Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
February 4th, 2014
Approaches for testing the effects of antipsychotic drugs (APDs) in Caenorhabditis elegans are demonstrated. Assays are described for testing drug effects on development and viability and on pharyngeal pumping rate. These methods are also applicable for pharmacogenetic experiments with drug classes other than APDs.
The overall goal of this procedure is to examine antipsychotic drug effects on the development and pharyngeal pumping of sea elgan. This is accomplished by first growing a population of adult nematodes and from them generating a synchronized population of animals. The next step is to transfer synchronized eggs or adults to drug laced assay plates.
The final step is to observe and score the effects of the drugs on the worms. Ultimately, the results can show that antipsychotic drugs delay development and inhibit pharyngeal pumping in drug exposed animals. Though this method can provide insight into the mechanisms of action of antipsychotic drugs, it can also be applied to study other small molecules and even large molecules such as lipids Have ready a drug of interest with a known working concentration.
Begin by loading a 12 well plate with two milliliters of NGM, medium per well. Set the plate aside to harden at room temperature. Next, pick a colony of OP 50 bacteria and transfer it to a 50 milliliter bottle of LB culture.
The bacteria overnight at 37 degrees Celsius with shaking at 220 RPM the next day into each well of the prepared plate. At 20 microliters of the bacterial culture, set the plate to incubate overnight at 37 degrees Celsius the following day. Load each seated well with 80 microliters of drug of interest at the working concentration.
In this case, the drug is C Clozapine. Be sure to vortex the solution before taking aliquots. Swirl the solution to distribute it evenly in the well and allow it to absorb at room temperature with the plate lid off.
Then proceed with the assay or store the plate at 20 degrees Celsius overnight and start the assay the next day. Begin by collecting eggs from the genotype of interest. Start with a population of worms with many GR adults.
Wash the worms off in a 3.5 centimeter plate using M nine buffer. Then spin them down in a 15 milliliter tube at 2000 RPM for one minute. Remove the supernatant via aspiration and replace it with five milliliters of bleach.
Then gently disrupt the adults by inverting the tube and wait for the animals to start dissolving continuously. Observe the dissolving worms under the scope. When about half the worms have dissolved.
After about five minutes, spin down the tube to collect the eggs, aspirate the supernatant, and quickly replace it with M nine buffer. Then spin the tube down again as before and remove all but about 100 microliters of the M nine supernatant. To suspend the eggs, vortex the tube.
Then transfer two microliters of the suspension to an NGM plate and count the number of transferred eggs. Then load the drug treated plate with 30 to 35 eggs per well and incubate the plate at 20 degrees Celsius for 24 hours. After 24 hours, score the number of hatched eggs.
If more than 25 worms are present in any, well remove the excess worms. Return the worms on the plate to the incubator for later observation at 24 hour intervals each day, score the developmental stage of the worms in the wells based on the size of the worms and the shape of their vulvas. Robust effects are usually seen on the third and fourth days.
The experiment should last about a week. For this protocol, have prepared drug test plates as previously described the day before, initiating the assay. Pick 50 L four stage animals for each genotype in the experiment.
Transfer them to NGM plates and incubate the plates for 24 hours at 20 degrees Celsius. The next day, every 15 to 20 minutes, load a test well with 10 animals after a group has been exposed to the drug for half an hour. Start observing their pharyngeal pumping under a dissection microscope.
First, find a worm, then count its pharyngeal pumps for 20 seconds. Once scored, pick the worm off the plate. Score all the worms in the well in the same manner.
The expected results of conducting the experimental delay. Lethality assay with wild type controls should show that unlike the typical growth rate to the grave, adult stage, animals exposed to c clozapine are still in the young larval stages or are dead testing mutants on different clozapine concentrations revealed suppressor mutants such as mute one and enhancer mutants such as MU two. Universally, the lethality of mute one was lower than wild type, and the lethality of MU two was higher as expected compared to the control surviving mute one animals are more able to develop, whereas mute two survivors are more delayed.
Further examination revealed that Clozapine exposure reduced the pharyngeal pumping rates in a concentration dependent manner. However, the decreased rate of mute one was less than that of wild type, while the decreased rate of mute two was greater than that of wild type. After watching this video, you should have a good understanding of how to perform antipsychotic drug assay on a small scale.
The message can also be scaled up to conduct a large scale genetic screen.
View the full transcript and gain access to thousands of scientific videos
Overview
This article demonstrates approaches for testing the effects of antipsychotic drugs (APDs) in Caenorhabditis elegans. The methods include assays for evaluating drug effects on development, viability, and pharyngeal pumping rate.
Key Study Components
Area of Science
- Neuroscience
- Pharmacology
- Developmental Biology
Background
- Caenorhabditis elegans is a model organism used for studying drug effects.
- Antipsychotic drugs can influence developmental processes.
- Pharyngeal pumping is a critical behavior for assessing drug impact.
- Pharmacogenetic experiments can be conducted using these methods.
Purpose of Study
- To examine the effects of antipsychotic drugs on nematode development.
- To assess the impact of these drugs on pharyngeal pumping rates.
- To provide insights into the mechanisms of action of APDs.
Methods Used
- Grow a population of adult Caenorhabditis elegans.
- Generate a synchronized population from adult nematodes.
- Transfer synchronized eggs or adults to drug-laced assay plates.
- Observe and score the effects of drugs on development and behavior.
Main Results
- Antipsychotic drugs delay development in exposed nematodes.
- Pharyngeal pumping is inhibited in drug-treated animals.
- Results can inform the understanding of drug mechanisms.
- Methods are applicable to other small and large molecules.
Conclusions
- The study provides a framework for testing drug effects in C. elegans.
- Insights gained can extend to various pharmacological studies.
- These methods can be adapted for broader applications beyond APDs.
Frequently Asked Questions
Executive Industry Relevance
Antipsychotic drug mechanism studies in C. elegans enable early target de-risking by linking phenotypic outcomes to neuromolecular pathways. The developmental and pharyngeal pumping assays provide quantitative, scalable readouts for mechanism-of-action interrogation in discovery biology. This supports predictive confidence in target validation and portfolio triage for neuropsychiatric indications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogate therapeutic hypotheses by linking antipsychotic exposure to developmental delay and pharyngeal inhibition phenotypes.
- Operational Value: Enable functional target validation through genetic suppressor and enhancer screens identifying modifiers of drug response.
- Predictive Value: Support mechanistic de-risking by revealing concentration-dependent effects on conserved neuromuscular outputs.
Screening & Assay Development
- Scientific Value: Prepare validated biological systems for downstream screening via synchronized embryo and staged adult preparation workflows.
- Operational Value: Address assay standardization through daily developmental scoring and 20-second pharyngeal pump counting protocols.
- Scalability Value: Highlight screening readiness and platform reuse for testing small and large molecules beyond antipsychotics.
Translational & Preclinical Research
- Translational Value: Discuss disease relevance through conserved neurotransmitter synthesis and synaptic function genes in C. elegans genome.
- Preclinical Continuity: Describe continuity from discovery through phenotypic validation in a whole-organism disease-relevant system.
- Risk-Adjusted Advancement: Address mechanism-based go/no-go decisions using developmental lethality and pumping rate suppression as efficacy biomarkers.
Pipeline & Workflow Integration
The method positions antipsychotic mechanism studies within early discovery to lead identification, supporting hypothesis testing and pathway clarification in neuropharmacology.
- Discovery Biology: Explain how the method supports hypothesis testing via developmental staging and pharyngeal pumping quantification.
- Screening: Describe assay readiness through synchronized egg transfer to drug-laced plates and daily phenotypic scoring.
- Analytics: Highlight quantitative outputs including developmental stage scoring and pharyngeal pumps per unit time for cross-condition comparison.
- Translational Research: Connect the method to preclinical continuity through conserved neuromuscular phenotypes predictive of drug mechanism.
- Enterprise Reuse: Frame the method as a reusable capability for mechanism-of-action studies across therapeutic areas using genetic and chemical screens.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through phenotypic anchoring of antipsychotic effects to neuromuscular function.
- Operational Value: Standardization and reproducibility via synchronized populations and defined scoring intervals for development and behavior.
- Strategic Value: Better go/no-go decisions by reducing mechanistic ambiguity in early antipsychotic screening.
- Portfolio Impact: Risk-adjusted prioritization using developmental delay and pharyngeal inhibition as translatable biomarker endpoints.
Implementation Considerations
- Required expertise in nematode culture, synchronization, and phenotypic scoring under dissection microscopy.
- Instrumentation needs include incubators, microscopes, and drug dispensing systems for 12-well plate assays.
- Cross-team standardization requires shared protocols for egg preparation, drug plating, and developmental staging criteria.
- Adaptation considerations across model systems involve conserving neurotransmitter targets and scaling assays for higher-throughput formats.
- Practical limitations include assay duration of approximately one week and sensitivity to bacterial lawn quality affecting worm health.
